AMERICAN TOWER CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued) Company is currently unable to estimate the impact of the amount of such changes, if any, to previously recorded uncertain tax positions.
A reconciliation of the beginning and ending amount of unrecognized tax benefits for the year ending December 31, 2007 is as follows (in thousands):
## Table 0 ##
During the year ended December 31, 2007, the Company recorded penalties and tax-related interest income of $2.5 million and interest income from tax refunds of $1.5 million for the year ended December 31, 2007.
As of December 31, 2007 and January 1, 2007, the total unrecognized tax benefits included in other long-term liabilities in the consolidated balance sheets was $29.6 million and $34.3 million, respectively.
As of December 31, 2007 and January 1, 2007, the total amount of accrued income tax-related interest and penalties included in other long-term liabilities in the consolidated balance sheets was $30.7 million and $33.2 million, respectively.
In the fourth quarter of 2007, the Company entered into a tax amnesty program with the Mexican tax authority.
As of December 31, 2007, the Company had met all of the administrative requirements of the program, which enabled the Company to recognize certain tax benefits.
This was confirmed by the Mexican tax authority on February 5, 2008.
These benefits include a reduction of uncertain tax benefits of $5.4 million along with penalties and interest of $12.5 million related to 2002, all of which reduced income tax expense.
In connection with the above program, the Company paid $6.7 million to the Mexican tax authority as a settlement offer for other uncertain tax positions related to 2003 and 2004.
This offer is currently under review by the Mexican tax authority; the Company cannot yet determine the specific timing or the amount of any potential settlement.
During 2007, the statute of limitations on certain unrecognized tax benefits lapsed, which resulted in a $0.7 million decrease in the liability for uncertain tax benefits, all of which reduced the income tax provision.
The Company files numerous consolidated and separate income tax returns, including U. S.  federal and state tax returns and foreign tax returns in Mexico and Brazil.
As a result of the Company’s ability to carry forward federal and state net operating losses, the applicable tax years remain open to examination until three years after the applicable loss carryforwards have been used or expired.
However, the Company has completed U. S.  federal income tax examinations for tax years up to and including 2002.
The Company is currently undergoing U. S.  federal income tax examinations for tax years 2004 and 2005.
Additionally, it is subject to examinations in various U. S.  state jurisdictions for certain tax years, and is under examination in Brazil for the 2001 through 2006 tax years and Mexico for the 2002 tax year.
SFAS No.109, “Accounting for Income Taxes,” requires that companies record a valuation allowance when it is “more likely than not that some portion or all of the deferred tax assets will not be realized.
” At December 31, 2007, the Company has provided a valuation allowance of approximately $88.2 million, including approximately
Medical and other expenses payable increased during 2003 and 2002 due primarily to medical claims inflation and increases in membership.
The timing of claim payments did not significantly impact 2003 or 2002 cash flows from operations.
The detail of medical and other expenses payable was as follows at December 31, 2003, 2002, and 2001:
## Table 1 ##
(1) IBNR represents an estimate of medical expenses payable for claims incurred but not reported (IBNR) at the balance sheet date.
The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle time, which represents the length of time between when a claim is initially incurred and when the claim form is received (i. e.  a shorter time span results in a lower IBNR).
(2) Unprocessed claim inventories represent the estimated valuation of claims received but not yet fully processed.
Further detail regarding unprocessed claim inventories is provided below.
(3) Processed claim inventories represent the estimated valuation of processed claims that are in the post claim adjudication process, which consists of administrative functions such as audit and check batching and handling.
(4) The balance due to our pharmacy benefit administrator fluctuates due to bi-weekly payments and the monthend cutoff and other medical expenses payable.
The timing of Medicare+Choice premium receipts may significantly impact our cash flows from operations in a particular period as the Medicare+Choice premium receipt is payable to us on the first day of each month.
When the first day of a month falls on a weekend or holiday, we receive this payment at the end of the previous month.
Since this amount is significant, the timing of its receipt can cause a material fluctuation in our operating cash flows from period to period.
The Medicare+Choice premium receipts for January 2004 of $211.9 million and for January 2003 of $205.8 million were received early in December 2003 and December 2002, respectively, because January 1 is a holiday.
This timing accounts for a significant portion of the unearned revenues balance on our consolidated balance sheets at December 31, 2003 and 2002.
Cash Flow from Investing Activities During 2003, we reinvested a portion of our operating cash flows in investment securities, primarily shortduration fixed income securities, totaling $283.1 million.
During 2003, 2002 and 2001, we also made capital expenditures as discussed below.
Cash Flow from Financing Activities During 2003, we converted our short-term commercial paper debt to long-term borrowings and repurchased common shares as discussed below.
The cash used in financing activities in 2002 resulted primarily from common share repurchases while the use of cash in 2001 resulted from reductions in borrowings.
Capital Expenditures Our ongoing capital expenditures primarily relate to our technology initiatives and administrative facilities necessary for activities such as claims processing, billing and collections, medical utilization review, and customer service.
Total capital expenditures, excluding acquisitions, were $101.3 million in 2003, $112.1 million
Humana Inc.  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued) Stock Based Compensation We have plans under which restricted stock awards and options to purchase our common stock have been granted to officers, directors, key employees and consultants.
Activity for our restricted stock awards was as follows for the years ended December 31, 2003, 2002 and 2001:
## Table 2 ##
Restricted stock awards generally vest three years from the date of grant.
Unearned compensation under the restricted stock award plans is amortized over the vesting periods.
Compensation expense recognized related to our restricted stock award plans was $5.8 million in 2003, $9.0 million in 2002, and $9.5 million in 2001.
The decrease in compensation expense in 2003 was due to the August 7, 2003 vesting of 3.9 million shares of restricted stock.
Options are granted at the average market price on the date of grant.
Exercise provisions vary, but most options vest in whole or in part 1 to 5 years after grant and expire 10 years after grant.
At December 31, 2003, there were 17,710,572 shares reserved for employee and director stock option plans, including 8,016,595 shares of common stock available for future grants.
As of February 24, 2004, a total of 2,540,114 additional options and awards were granted.
Activity for our option plans was as follows for the years ended December 31, 2003, 2002 and 2001:
## Table 3 ##

Tables referenced above, in order (Table 0 first):
<table><tr><td>Balance at January 1, 2007</td><td>$183,953</td></tr><tr><td>Additions based on tax positions related to the current year</td><td>2,598</td></tr><tr><td>Additions for tax positions of prior years</td><td>5,412</td></tr><tr><td>Reductions for tax positions of prior years</td><td>-120,016</td></tr><tr><td>Cash advance in connection with proposed settlement</td><td>-6,682</td></tr><tr><td>Settlements with taxing authorities</td><td>-5,372</td></tr><tr><td>Reductions as a result of the lapse of statute of limitations</td><td>-669</td></tr><tr><td>Balance as of December 31, 2007</td><td>$59,224</td></tr></table>
<table><tr><td></td><td></td><td></td><td></td><td colspan="2">Change</td></tr><tr><td></td><td> 2003 </td><td> 2002 </td><td> 2001 </td><td>2003</td><td>2002</td></tr><tr><td></td><td colspan="5">(in thousands)</td></tr><tr><td>IBNR-1</td><td>$1,034,858</td><td>$863,432</td><td>$802,574</td><td>$171,426</td><td>$60,858</td></tr><tr><td>Unprocessed claim inventories-2</td><td>109,700</td><td>92,300</td><td>125,400</td><td>17,400</td><td>-33,100</td></tr><tr><td>Processed claim inventories-3</td><td>74,262</td><td>105,422</td><td>102,622</td><td>-31,160</td><td>2,800</td></tr><tr><td>Payable to pharmacy benefit administrator and other-4</td><td>53,336</td><td>80,977</td><td>55,790</td><td>-27,641</td><td>25,187</td></tr><tr><td>Total medical and other expenses payable</td><td>$1,272,156</td><td>$1,142,131</td><td>$1,086,386</td><td>$130,025</td><td>$55,745</td></tr></table>
<table><tr><td></td><td>2003</td><td>2002</td><td>2001</td></tr><tr><td>Balance, January 1,</td><td>4,131,726</td><td>4,733,000</td><td>5,047,500</td></tr><tr><td>Granted—treasury issuance</td><td>—</td><td>—</td><td>125,000</td></tr><tr><td>Granted—original issuance</td><td>—</td><td>—</td><td>30,000</td></tr><tr><td>Total granted</td><td>—</td><td>—</td><td>155,000</td></tr><tr><td>Vested</td><td>-3,904,382</td><td>-270,000</td><td>-6,000</td></tr><tr><td>Forfeited</td><td>-72,344</td><td>-331,274</td><td>-463,500</td></tr><tr><td>Balance, December 31,</td><td>155,000</td><td>4,131,726</td><td>4,733,000</td></tr></table>
<table><tr><td></td><td>Shares Under Option</td><td colspan="3"> Exercise Price Per Share </td><td> Weighted Average Exercise Price </td></tr><tr><td>Balance, January 1, 2001</td><td>11,390,017</td><td>$6.41</td><td>to</td><td>$26.94</td><td>$13.41</td></tr><tr><td>Granted</td><td>935,500</td><td>9.37</td><td>to</td><td>14.94</td><td>11.30</td></tr><tr><td>Exercised</td><td>-236,878</td><td>6.50</td><td>to</td><td>9.59</td><td>7.66</td></tr><tr><td>Canceled or lapsed</td><td>-1,630,691</td><td>6.50</td><td>to</td><td>23.44</td><td>16.71</td></tr><tr><td>Balance, December 31, 2001</td><td>10,457,948</td><td>6.41</td><td>to</td><td>26.94</td><td>12.84</td></tr><tr><td>Granted</td><td>1,588,000</td><td>11.55</td><td>to</td><td>15.40</td><td>12.99</td></tr><tr><td>Exercised</td><td>-973,647</td><td>6.50</td><td>to</td><td>15.59</td><td>8.76</td></tr><tr><td>Canceled or lapsed</td><td>-545,430</td><td>6.50</td><td>to</td><td>20.16</td><td>15.36</td></tr><tr><td>Balance, December 31, 2002</td><td>10,526,871</td><td>6.41</td><td>to</td><td>26.94</td><td>13.11</td></tr><tr><td>Granted</td><td>2,500,000</td><td>9.26</td><td>to</td><td>19.73</td><td>11.51</td></tr><tr><td>Exercised</td><td>-2,646,578</td><td>6.41</td><td>to</td><td>20.16</td><td>10.59</td></tr><tr><td>Canceled or lapsed</td><td>-686,316</td><td>6.50</td><td>to</td><td>23.06</td><td>15.47</td></tr><tr><td>Balance, December 31, 2003</td><td>9,693,977</td><td>$6.50</td><td>to</td><td>$26.94</td><td>$13.22</td></tr></table>

Question: What is the average amount of Balance, December 31, 2001 of Shares Under Option, and Balance, January 1, of 2003 ?
Answer: 7.29484e+06
Reasoning program: add(10457948.0,4131726.0), divide(#0,const_2)